These findings demonstrate that dLGG and doxorubicin inhibit primary tumor growth, relapse, and metastasis at least in part via dual deregulation of FABP4 and FABP5 in metastatic TNBC tumors. The gene discussed is FABP4; the disease is neoplasm.